Roivant Sciences has launched a seamless Phase 2b/3 clinical program for its dual TYK2/JAK1 inhibitor brepocitinib in lichen planopilaris (LPP), a rare inflammatory scalp disorder that affects roughly 100,000 U.S. adults and for which no FDA‑approved therapies exist. The first patients were enrolled in March 2026, and the expansion represents the fourth indication in brepocitinib’s late‑stage pipeline, which also includes dermatomyositis, non‑infectious uveitis and cutaneous sarcoidosis.
The LPP program is positioned to leverage Roivant’s existing prescriber networks in dermatology and rheumatology, targeting a highly morbid orphan condition with a clear unmet need. By adding LPP, Roivant aims to broaden its market reach and capitalize on shared therapeutic mechanisms across its portfolio.
In parallel, Roivant disclosed topline data from two Phase 3 studies of its FcRn blocker batoclimab in thyroid eye disease (TED). Both studies failed to meet the primary endpoint of a ≥2 mm proptosis responder rate at week 24. Safety data were consistent with earlier trials and no new safety signals emerged, although greater proptosis improvement was observed during the initial high‑dose period compared to the subsequent low‑dose phase.
Following the TED results, Roivant and its subsidiary Immunovant are pivoting toward the next‑generation FcRn blocker IMVT‑1402, with top‑line data for Graves’ disease expected in 2027. The batoclimab setback underscores the challenges of translating IgG‑depletion strategies into clinical benefit for TED.
Roivant’s financial position remains robust, with an unaudited cash, cash equivalents and marketable securities balance of approximately $4.3 billion as of March 31 2026. The company reported a net loss of $252.4 million for Q4 FY2025 and an EPS of –$0.33 for Q1 2026, falling short of the $7.69 million revenue forecast. These figures illustrate the company’s continued investment in its pipeline despite operating losses.
"Expanding brepocitinib into lichen planopilaris continues our strategy of developing therapies in highly morbid orphan conditions with limited treatment options and distinctive mechanistic benefits," said Ben Zimmer, CEO of Roivant. The statement highlights the strategic rationale behind the LPP expansion and the company’s focus on rare disease opportunities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.